TG Therapeutics, Inc. (TGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$55.99-1.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TGTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 106.0% |
| Our one-year growth estimate | diamond | 45.9% |
Growth built into the price is above our model estimate.
The price assumes 60.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TGTX — earnings miss
Dated 2026-08-03
of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Good results could confirm the new single infusion treatment for BRIUMVI. This may make treatment easier for patients and improve market position.
Supportive ifTopline results show the new single infusion works like the current treatment. The GMR is around 1.0.
Worry ifResults indicate no bioequivalence, with GMR outside the defined range of 0.80 to 1.25.
Why it matters: This will show if the company's growth strategy is still working. A drop could signal trouble.
Worry ifQ2 revenue growth reported below 25% year over year.
Less concerning ifQ2 revenue growth remains at or above 25% year over year.
Why it matters: Progress on this project could increase BRIUMVI's market chances. Success helps long-term growth.
Supportive ifNews about progress or good results in the subcutaneous BRIUMVI program.
Worry ifNo news or bad results about BRIUMVI's skin injection development.
Why it matters: Filing for the new dosing could speed up approval. It may also increase revenue.
Supportive ifManagement will file a new BLA for the single infusion by the end of 2026.
Worry ifNo supplemental BLA is filed by the end of 2026.
Why it matters: Full results could confirm the easier dosing for BRIUMVI. This may improve patient experience and increase use.
Supportive ifFull results from the Phase 3 ENHANCE trial confirm the safety of the new dosing.
Worry ifThe results show safety problems. There is no equivalence between dosing methods.
Why it matters: This shows the company is managing costs well. A rise in operating income is a good sign.
Supportive ifQ2 operating income was over $40M.
Worry ifQ2 operating income was under $30M.
Why it matters: Higher operating costs can lead to issues in managing expenses. This can hurt profits.
Worry ifQ2 2026 SG&A expenses remain stable or decrease compared to Q1 2026.
Less concerning ifQ2 2026 SG&A expenses are much higher than Q1 2026.
Why it matters: A drop in sector growth could hurt TG Therapeutics. It shows broader challenges in the health care sector.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Managing costs well is important for making money. Rising costs could hurt future earnings.
Worry ifSG&A expenses stabilize or decrease in the next quarter.
Less concerning ifSG&A expenses continue to rise beyond $90 million in the next quarter.
Why it matters: Higher costs can reduce profits. This may lower investor confidence.
Worry ifOperating costs for 2026 will exceed $400 million.
Less concerning ifOperating expenses will stay within the range of $350-400 million.
Why it matters: This would indicate a setback in achieving positive net income. It could hurt investor confidence.
Worry ifQ2 net income reported as negative.
Less concerning ifQ2 net income reported as positive.
Why it matters: Topline data will show if the new subcutaneous formulation meets its main goal. This could greatly expand the market for BRIUMVI.
Supportive ifTopline Phase 3 data shows drug exposure is similar to IV BRIUMVI.
Worry ifThe main data does not show that the subcutaneous formulation is as good.
Why it matters: Filing for the ENHANCE trial results could lead to a quicker approval process for the new dosing regimen.
Supportive ifA supplemental BLA is filed based on the positive ENHANCE trial results.
Worry ifNo supplemental BLA is filed by the end of 2026.
Why it matters: Continued revenue growth will show BRIUMVI's strong performance. It will also support management's guidance.
Supportive ifQ3 U.S. net product revenue for BRIUMVI exceeds $227.7 million.
Worry ifQ3 U.S. net product revenue falls below $200 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$156 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $348 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,685 loss on $10,000 · 26.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.